Chronic myeloid leukemia (CML) is effectively treated with tyrosine kinase inhibitors (TKIs), targeting the BCR::ABL1 oncoprotein. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.